Full Breakdown
New Trial Suggests Active Surveillance for Low-Risk DCIS May Be Effective
4/1/2026, 1:20:14 AM
Overview of the Clinical Trial Findings
A recent clinical trial has indicated that a "watch and wait" approach may be a viable option for women diagnosed with low-risk ductal carcinoma in situ (DCIS), a precancerous breast condition. Conducted by researchers from The Netherlands Cancer Institute and presented at the European Breast Cancer Conference in Barcelona, Spain, the study involved over 1,400 women treated at approximately 60 hospitals in the Netherlands. The trial began in 2017, initially assigning 73 participants to either immediate surgery or active surveillance, with subsequent patients allowed to choose their treatment option. Notably, around 75% opted for active surveillance.
Key Findings and Implications
The trial's results revealed that 9% of women who underwent surgery developed invasive cancer, compared to 6% in the active surveillance group. Although tumors detected in the active surveillance cohort were slightly larger on average (6 mm versus 9 mm), they were not found to be more aggressive. These findings suggest that many cases of DCIS may be subject to overtreatment, raising questions about the necessity of immediate surgical intervention.
Dr. Jelle Wesseling, a leading researcher in the study, emphasized the importance of monitoring patients closely while keeping surgical options available. He stated, “For women with low-risk DCIS, these interim results are reassuring,” and highlighted the need for further research before altering existing breast cancer treatment guidelines.
Expert Opinions
Dr. Isabel Rubio, chair of the meeting and head of breast surgical oncology at the University of Navarra Clinic in Madrid, concurred with Wesseling's assessment. She noted that while surgery is currently the standard treatment for most DCIS patients, the findings could support a more conservative approach for selected individuals. Rubio remarked, “With longer follow-up, these findings may help support a more de-escalated approach to care for selected patients, suggesting that carefully monitored active surveillance could offer outcomes similar to surgery, while avoiding overtreatment.”
Criticism and Future Considerations
Despite the promising results, experts caution that these findings are preliminary and require further validation through peer-reviewed publications. Wesseling reiterated the medical principle of “first, do no harm,” stressing the goal of minimizing unnecessary treatments without compromising patient safety. The ongoing debate surrounding the treatment of DCIS underscores the need for continued research and discussion within the medical community.
Conclusion
The trial's findings present a potential shift in the management of low-risk DCIS, advocating for active surveillance as a safe alternative to immediate surgery. As the medical community evaluates these results, the implications for treatment guidelines and patient care may evolve, potentially leading to a more tailored approach in managing this common precancerous condition.
